Upcoming Pfizer launches
Anti-migraine agent Relpax (eletriptan) "is probably one of those things that is going to be a year-end approval kind of situation," Pfizer Global R&D President John Niblack told a July 26 conference call. Pfizer has responded to a 1999 "approvable" letter, and FDA has six months to review the resubmission, he said. The antihistamine/ decongestant combo Zyrtec D should be approved during the first quarter, Pfizer said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth